GlassScriptPhysician profile
Heather G Gray
NPI 1568645885
$1,847.75
in general payments reported to CMS, 2019-2025
30 companies · $95.83 in 2025
The $95.83 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $599 · 2023: $345 · 2024: $316 · 2025: $95.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.32 | 2021-2024 | |
| Lilly USA, LLC | $184.69 | 2021-2024 | Jardiance, Mounjaro |
| Amgen INC. | $149.94 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $124.48 | 2021-2024 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $115.34 | 2022 | |
| Astellas Pharma US INC | $103.76 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $84.78 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.15 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.56 | 2022-2023 | Austedo, Austedo Xr |
| Nestle Healthcare Nutrition INC. | $54.87 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.65 | 2021-2022 | |
| Pfizer INC. | $51.20 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $48.82 | 2021-2023 | Spravato |
| Amarin Pharma, INC. | $46.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.24 | 2021-2023 | Trulance, Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.03 | 2023-2024 | Cologuard Collection Kit |
| Baxter Healthcare | $27.08 | 2022 | |
| Glaxosmithkline, LLC. | $26.35 | 2021 | |
| Sanofi Pasteur INC. | $25.00 | 2022 | |
| Mirati Therapeutics, INC. | $24.42 | 2024 | Krazati |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.30 | 2022 | |
| Merck Sharp & Dohme LLC | $19.47 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.15 | 2021 | |
| Alkermes, INC. | $18.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.23 | 2021 | |
| Sumitomo Pharma America, INC. | $14.88 | 2024 | Gemtesa |
| Edwards Lifesciences Corporation | $13.89 | 2022 | |
| Cranial Technologies, INC | $13.18 | 2021 | |
| Grifols USA, LLC | $12.09 | 2021 | |
| Reflow Medical INC | $10.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.